Prohibition of Human Cloning for Reproduction Act 2002

The Act defines several critical terms in section 8. A human embryo is a discrete entity that has arisen from either the first mitotic division when fertilisation of a human oocyte by a human sperm is complete, or any other process that initiates organised development of a biological entity with a human nuclear genome or altered human nuclear genome that has the potential to develop up to or beyond the stage at which the primitive streak appears, and has not yet reached eight weeks of development since the first mitotic division. Development time excludes any suspended period. Importantly, the term does not include a hybrid embryo or a human embryonic stem cell line (section 8(8)).

A human embryo clone is a human embryo that is a genetic copy of another living or dead human, but does not include a human embryo created by the fertilisation of a human egg by human sperm. Section 8(2) provides that for the purposes of establishing a genetic copy, it is sufficient that the set of genes in the nuclei of the cells has been copied; it is not necessary to show an identical genetic copy. Furthermore, an embryo resulting from embryo splitting is taken not to be created by fertilisation, so it falls within the definition of a clone.

A chimeric embryo is a human embryo into which a cell or any component part of a cell of an animal has been introduced, or a thing declared by the regulations to be such. A hybrid embryo has a broader definition: (a) an embryo created by fertilisation of a human egg by animal sperm; (b) an embryo created by fertilisation of an animal egg by human sperm; (c) a human egg into which the nucleus of an animal cell has been introduced; (d) an animal egg into which the nucleus of a human cell has been introduced; or (e) a thing declared by regulations. The Act distinguishes between chimeric and hybrid embryos and imposes different offence provisions for each.

An excess ART embryo is a human embryo created by assisted reproductive technology for use in the treatment of a woman and that is excess to the needs of the woman and her spouse at the time of creation. Section 8(5) provides that an embryo is excess if each such person has given written authority for use of the embryo for a purpose other than ART treatment and that authority is in force, or each such person has determined in writing that the embryo is excess to their needs and that determination is in force.

Precursor cell means a cell that has the potential to develop into a human egg or human sperm. This concept is used in section 23A, which prohibits using precursor cells taken from a human embryo or fetus to create a human embryo without a general licence. Human sperm includes human spermatids.

The Act also defines mitochondrial donation licence to mean any of five types of licences issued under section 28J of the RIHE Act: pre-clinical research and training licence, clinical trial research and training licence, clinical trial licence, clinical practice research and training licence, and clinical practice licence. Mitochondrial donation technique has the same meaning as in Part 2 of the RIHE Act. These licences create exceptions to several key offences, including creating an embryo for a purpose other than pregnancy (section 12), creating an embryo with genetic material from more than two persons (section 13), heritable alterations to the genome (section 15), and placing a prohibited embryo in a woman (section 20(3)). The Act also defines general licence by reference to Part 2 of the RIHE Act.

Prohibited embryo is defined in section 20(4) and covers eight categories, including embryos created without fertilisation, embryos created outside the body without an intention to achieve pregnancy, embryos with genetic material from more than two persons, embryos developed beyond 14 days, embryos created using precursor cells from embryos or fetuses, embryos with heritable genome alterations, embryos removed from a woman intending to collect a viable embryo, and chimeric or hybrid embryos. The definition is central to the import, export, and placement offences in section 20.

The Act applies to a broad but constitutionally anchored range of persons and activities. Section 4(1) specifies that the Act applies to things done or omitted to be done by constitutional corporations, to things done in the course of constitutional trade or commerce, to matters within the external affairs power (paragraph 51(xxix)), to the Commonwealth and Commonwealth authorities, to purposes relating to statistics, and to matters incidental to those heads of power under paragraph 51(xxxix). A constitutional corporation means a trading, foreign or financial corporation within the meaning of paragraph 51(xx) of the Constitution. Constitutional trade or commerce includes trade or commerce between Australia and places outside Australia, among the States, or by way of supply of services to the Commonwealth or a Commonwealth authority.

This means the Act primarily affects entities that are constitutional corporations, such as private hospitals, IVF clinics operated by companies, commercial research organisations, and pharmaceutical and biotechnology companies. It also affects individuals and entities engaged in interstate or international trade or commerce related to human embryos, gametes, or reproductive technology. The Commonwealth itself and its authorities are directly bound. The statistics purpose ensures that the Act can apply to the collection and analysis of data relating to assisted reproductive technology, which is often carried out by the Australian Institute of Health and Welfare and similar bodies.

The Act binds the Crown in all capacities, though section 5(2) provides that nothing in the Act renders the Crown liable to prosecution. This means that public hospitals and other government entities are bound by the prohibitions, but cannot be criminally prosecuted; nevertheless, the individuals working within them who are not the Crown may face prosecution. The Act extends to every external Territory, so it applies in Norfolk Island, Christmas Island, the Cocos (Keeling) Islands, and other Australian external territories.

Researchers and clinicians are directly affected. Those who create human embryos by fertilisation outside a woman's body may do so only with the intention of attempting to achieve pregnancy in a particular woman or under a mitochondrial donation licence (section 12). This prohibits the creation of embryos solely for research purposes unless a licence is obtained. Scientists working on somatic cell nuclear transfer or other cloning techniques are prohibited from creating human embryo clones unless authorised by a licence. The 14-day rule in section 14 affects all researchers developing human embryos outside the body, including clones and other embryos.

Importers and exporters of embryos, gametes, or stem cell lines are affected by sections 10 and 20, which prohibit importing or exporting human embryo clones or prohibited embryos. Section 23C imposes a duty on the Customs Minister to make regulations permitting the import and export of human embryonic stem cell lines derived from human embryo clones using practices consistent with Australian legislation, so there is a pathway for such trade under regulation.

Commercial traders in human eggs, sperm, or embryos are directly targeted by section 21, which prohibits giving or receiving valuable consideration for the supply of these biological materials. Non-profit donors and recipients can still cover reasonable expenses.

Finally, the Act affects the States and Territories through the cooperative scheme. Section 24 provides that the Act is not intended to exclude the operation of any State law to the extent that the State law is capable of operating concurrently. This means State legislation regulating ART, such as the Assisted Reproductive Treatment Acts in various States, can continue alongside the Commonwealth prohibitions.

The central duty imposed by the Act is the obligation not to engage in any of the prohibited practices set out in Part 2. These duties are structured as criminal offences with a fault element of intention. The key prohibitions create duties not to: place a human embryo clone in a human or animal (section 9); import or export a human embryo clone (section 10); create a human embryo by fertilisation outside the body unless for achieving pregnancy or under a mitochondrial donation licence (section 12); create or develop an embryo by fertilisation with genetic material from more than two persons (section 13); develop a human embryo outside the body for more than 14 days (section 14); alter the genome of a human cell in a way that is heritable (section 15); remove a viable human embryo from a woman (section 16); create a chimeric embryo (section 17); develop a hybrid embryo for more than 14 days (section 18); place a human embryo in an animal or outside the female reproductive tract, or place an animal embryo in a human (section 19); import, export, or place a prohibited embryo (section 20); give or receive valuable consideration for supply of gametes or embryos (section 21); create or develop a human embryo by a process other than fertilisation (section 22); create or develop an embryo with genetic material from more than two persons by a process other than fertilisation (section 23); use precursor cells from an embryo or fetus to create an embryo (section 23A); and create or develop a hybrid embryo (section 23B).

Alongside these duties, the Act confers certain rights and defences. The most significant right is the ability to carry out activities under a licence. Section 12 permits creation of an embryo by fertilisation if the intention is to achieve pregnancy or if the creation is permitted under section 28B of the RIHE Act (mitochondrial donation licences). Sections 13 and 15 contain similar exceptions for activities permitted under mitochondrial donation licences. Sections 22 and 23 allow creation or development of embryos by other processes if authorised by a general licence or a mitochondrial donation licence. Section 23B(3) provides a defence to the hybrid embryo offence if the creation or development is authorised by a general licence. Section 23BA provides a right not to be criminally responsible for a licence offence if the conduct was purportedly authorised by a licence that is invalid, and the person did not know and could not reasonably be expected to have known of the invalidity. This protection applies to general licences and mitochondrial donation licences.

Another important right is the ability to pay and receive reasonable expenses for the supply of human eggs, human sperm, or human embryos. Section 21(3) defines reasonable expenses broadly to include collection, storage, and transport costs, but for embryos, expenses incurred before the embryo became an excess ART embryo are not included. The payment of reasonable expenses does not constitute valuable consideration, so it is not an offence.

The Act also provides that a defendant does not bear an evidential burden in relation to certain matters. Section 12(2) states that despite subsection 13.3(3) of the Criminal Code, a defendant does not bear an evidential burden in relation to any matter in subsection 12(1). Similarly, section 20(5) removes the evidential burden from a defendant in relation to subsection 20(3). This means the prosecution must prove the absence of any applicable exception.

The Act imposes severe penalties, the highest being imprisonment for 15 years for the most serious offences. The following offences carry a maximum penalty of 15 years' imprisonment: placing a human embryo clone (section 9); importing or exporting a human embryo clone (section 10); creating an embryo by fertilisation for an improper purpose (section 12); creating or developing an embryo with genetic material from more than two persons by fertilisation (section 13); developing an embryo outside the body for more than 14 days (section 14); making heritable alterations to the genome (section 15); collecting a viable human embryo (section 16); creating a chimeric embryo (section 17); developing a hybrid embryo for more than 14 days (section 18); placing an embryo in an animal, outside the female reproductive tract, or placing an animal embryo in a human (section 19); importing, exporting, or placing a prohibited embryo (section 20); and commercial trading in human eggs, sperm or embryos (section 21). Each of these offences requires proof of intention. The Act does not impose fines or corporate penalties; the sole penalty for individuals is imprisonment.

A second tier of offences carries a maximum penalty of 10 years' imprisonment. These include: creating or developing a human embryo by a process other than fertilisation without authorisation (section 22); creating or developing an embryo with genetic material from more than two persons by a process other than fertilisation without authorisation (section 23); using precursor cells from a human embryo or fetus to create an embryo without a general licence (section 23A); and creating or developing a hybrid embryo without authorisation (section 23B). The distinction in penalties reflects the view that creation by fertilisation for non-reproductive purposes is more serious than creation by other processes, and that hybrid embryo activities are less serious when conducted without a licence compared to activities involving human embryos directly.

The Act contains several features that strengthen enforcement. Section 11 explicitly provides that it is not a defence to an offence under section 9 or 10 that the human embryo clone did not survive or could not have survived. This removes any argument that the embryo was non-viable and therefore not a relevant entity. Section 12(2) and section 20(5) reverse the usual evidential burden provisions of the Criminal Code. Normally, a defendant bears an evidential burden in relation to an exception or defence, but these provisions state that the defendant does not bear an evidential burden in relation to matters in those subsections. This means the prosecution must prove beyond reasonable doubt that none of the exceptions apply, which could make prosecution more difficult but ensures that the burden of proof remains on the state.

The Crown is bound by the Act but cannot be prosecuted for an offence (section 5(2)). This means that while government employees and agencies must comply, the only enforcement mechanism against the Crown itself would be injunctive or declaratory relief, not criminal prosecution. The Act does not create a civil penalty regime; enforcement relies entirely on criminal prosecution under Commonwealth law, which would be undertaken by the Commonwealth Director of Public Prosecutions. There are no provisions for licensing, inspection, or regulatory enforcement within this Act; such mechanisms are found in the Research Involving Human Embryos Act 2002.

The Act is part of a legislative package dealing with assisted reproductive technology and embryo research. Its principal companion is the Research Involving Human Embryos Act 2002 (the RIHE Act), which establishes the NHMRC Licensing Committee and provides for general licences and mitochondrial donation licences. Several provisions of this Act refer directly to the RIHE Act. Section 12(1)(b) allows creation of an embryo by fertilisation if permitted under section 28B of the RIHE Act (carrying out activities authorised by mitochondrial donation licences). Sections 13(c), 15(1)(c), 20(3)(b), 22(b), 23(c), and 23B(3) all contain similar cross-references to licences under the RIHE Act or its section 28B. The Act defines general licence as having the same meaning as in Part 2 of the RIHE Act, and mitochondrial donation licence as defined in section 28J of that Act.

Section 24 provides that this Act is not intended to exclude the operation of any law of a State to the extent that the State law is capable of operating concurrently. This is a standard provision to preserve State legislation on similar topics, such as the various State Assisted Reproductive Technology Acts (e.g., in Victoria, New South Wales, Western Australia, South Australia, and Queensland). A person may face prosecution under both Commonwealth and State law for the same conduct, as long as the State law is consistent and does not conflict with the Commonwealth Act.

The Act interacts with the Criminal Code. Section 12(2) and section 20(5) explicitly refer to subsection 13.3(3) of the Criminal Code, which deals with evidential burdens. These provisions override the default position to ensure the defendant does not bear an evidential burden regarding the exceptions in sections 12 and 20. The rest of the Criminal Code applies to all offences under this Act, including the fault elements, defences, and procedural provisions.

The Act also intersects with the Customs Act 1901. Section 23C imposes a duty on the Minister administering the Customs Act to take all reasonable steps to ensure regulations are made within six months after the commencement of that section to permit, subject to appropriate conditions or restrictions, the import and export of human embryonic stem cell lines that have been derived from human embryo clones using practices consistent with Australian legislation. This means that the Customs (Prohibited Imports) Regulations and Customs (Prohibited Exports) Regulations must be amended to allow such trade when consistent with the Act.

The Acts Interpretation Act 1901 is relevant for the definition of spouse, which includes a de facto partner within the meaning of that Act. The Acts Interpretation Act also provides rules about periodic reports, as noted in section 25(4) of this Act. There is no reference to any other Commonwealth laws such as the Therapeutic Goods Act or the Gene Technology Act in the source text, so we cannot discuss them.

The Act provides for regulation-making power in section 26. Regulations can prescribe matters required or permitted by the Act, and must be made after consultation with the States. The regulations can declare things to be chimeric embryos or hybrid embryos, as per the definitions in section 8.

The Act was originally passed in 2002 and received Royal Assent on 19 December 2002. Sections 1 and 2 commenced on that date, and sections 3 to 26 and Schedule 1 commenced on 16 January 2003 (the 28th day after Royal Assent). The Act as originally enacted did not contain any references to mitochondrial donation licences or the detailed licensing framework for such techniques.

The most significant amendment to the Act came from the Mitochondrial Donation Law Reform (Maeve's Law) Act 2022. The source text includes references to this amendment in several places. Section 4(1) contains a note referring to section 28B of the Research Involving Human Embryos Act 2002 in relation to mitochondrial donation licences. Section 25, the review provision, was substantially amended or inserted by this reform: it requires the Minister to cause an independent review of the operation of the Act in so far as it relates to the use of mitochondrial donation techniques, to be undertaken as soon as possible after the end of the period of seven years starting on the commencement of Schedule 1 to the Mitochondrial Donation Law Reform (Maeve's Law) Act 2022, and each subsequent seven-year period. The review must be undertaken by persons chosen by the Minister with the agreement of each State, and the report must be given to the Minister within 12 months after the end of the relevant period. The reviewers must consult the Commonwealth, the States, and a broad range of persons with expertise in relevant disciplines, and the views must be set out in the report to the extent reasonably practicable.

The 2022 amendment also inserted several new provisions into the Act. Section 23BA (Person not liable for conduct purportedly authorised) was introduced to protect persons acting under invalid licences. Section 23C (Regulations under Customs Act) was also added at that time. The definition of mitochondrial donation licence and mitochondrial donation technique were included as part of this reform. Additionally, sections 12, 13, 15, 20, 22, and 23 were amended to include the words "or permitted under section 28B of the Research Involving Human Embryos Act 2002 (carrying out activities authorised by mitochondrial donation licences)" to allow such activities to proceed without offending the prohibitions.

The Act does not contain any other amendment history in the provided text. The note to the commencement table states that the table relates only to the provisions as originally passed and will not be expanded to deal with provisions inserted after assent, so the table does not show the 2022 amendments. Nonetheless, the text of the Act as currently in force reflects those amendments.

The source text does not refer to any specific litigation or court cases involving this Act. The Act itself provides only for a review mechanism under section 25, which requires periodic independent reviews focusing on the operation of the Act in relation to mitochondrial donation techniques. The Act does not include any provisions for civil remedies, enforcement orders, or administrative appeals that would generate litigation. Enforcement is by criminal prosecution under the Commonwealth criminal justice system, and any litigation would be conducted in the ordinary courts. There is no mention in the Act of any existing or concluded cases, nor of any constitutional challenges.

Given that the Act operates primarily through the threat of criminal penalties and the licensing scheme under the Research Involving Human Embryos Act 2002, litigation may arise in the context of prosecutions or in cases involving the validity of licences. The relatively recent introduction of the mitochondrial donation framework in 2022 may lead to future litigation as licences are issued and activities commence. The protection in section 23BA for conduct purportedly authorised by an invalid licence is designed to reduce the risk of litigation where a licence has a technical defect.

The Act does not create a private right of action or a statutory tort. It does not provide for civil penalties or infringement notices. The only enforcement mechanism is criminal prosecution, which would require a case to be brought by the Commonwealth Director of Public Prosecutions. As of the text provided, there is no reference to any judicial interpretation of the definitions or offences. The absence of litigation history in the source does not mean no cases exist, but we cannot speculate.

The review provisions in section 25, amended in 2022, ensure that the operation of the Act in relation to mitochondrial donation is reviewed at least every seven years. The first review period starts from the commencement of Schedule 1 to the Mitochondrial Donation Law Reform (Maeve's Law) Act 2022, and the report must be given within 12 months after that period. These reviews may consider whether any litigation has occurred and whether the Act is operating effectively, but that is a future matter.

Several provisions in the Act create potential traps for the unwary. The first concerns the definition of human embryo clone in section 8(1) and the interaction with section 8(4). A human embryo clone is defined as a human embryo that is a genetic copy of another living or dead human, but does not include an embryo created by the fertilisation of a human egg by human sperm. Section 8(4) provides that an embryo resulting from embryo splitting is taken not to be created by fertilisation. Therefore, an embryo created by splitting a naturally fertilised embryo is treated as a clone, even though it is not a product of nuclear transfer. This means that placing, importing, or exporting such an embryo would be an offence under sections 9 and 10, with no defence that it could not survive (section 11).

The 14-day rule in section 14 applies to the development of a human embryo outside the body of a woman. However, for the purposes of measuring the 14-day period, any period when development is suspended is to be disregarded (section 8(3)). This means that cryopreservation or other suspension of development does not count towards the 14 days. A researcher could potentially keep an embryo frozen for years and then thaw and culture it for up to 14 days, but the total time outside the body (including the frozen period) would be much longer. The critical point is that the 14-day limit applies only to periods of active development.

Another trap is in section 12(2) and section 20(5), which state that the defendant does not bear an evidential burden in relation to the exceptions in those sections. In criminal law, an evidential burden usually requires the defendant to point to some evidence that an exception might apply. Here, the prosecution must prove the absence of the exception beyond reasonable doubt. While this may appear favourable to a defendant, it also means that the prosecution may need to adduce extensive evidence showing that the embryo was not created for the purpose of achieving pregnancy, or that the embryo did not fall within a licensing exception. It is a subtle but important point.

The definition of excess ART embryo in section 8(5) requires that both the woman for whom the embryo was created and her spouse (if any) have given written authority for use of the embryo for a purpose other than ART treatment, or have determined in writing that the embryo is excess to their needs. If only one person consents, the embryo is not an excess ART embryo for the purposes of the Act. This affects the ability to use such an embryo in research and also affects the definition of reasonable expenses in section 21, which for embryos excludes expenses incurred before the embryo became an excess ART embryo. If an embryo is not legally excess, no reasonable expenses can be paid for its supply, and any payment would constitute an offence.

The commercial trading prohibition in section 21 includes any inducement, discount, or priority in the provision of a service as valuable consideration. This means that a clinic offering discounted IVF treatment in exchange for egg donation would be giving valuable consideration, even if no money changes hands. The exception for reasonable expenses is carefully circumscribed, and for embryos, expenses incurred before the embryo became an excess ART embryo are not reasonable expenses. This creates a trap for clinics that might seek to reimburse donors for costs incurred before the embryo was declared excess.

Section 23A creates an offence for using precursor cells from a human embryo or human fetus to create a human embryo, unless authorised by a general licence. The offence requires knowledge or recklessness as to the lack of authorisation. This is narrower than other offences that only require intention to perform the act. A scientist who obtains precursor cells from a reputable source but fails to check whether a licence is in place may be reckless and therefore liable.

Compliance with the Prohibition of Human Cloning for Reproduction Act 2002 requires careful structuring of all activities involving the creation, use, storage, transfer, and disposal of human embryos, human gametes, and precursor cells. The first step is to determine whether the proposed activity falls within any of the prohibited practices in Part 2. If it does, the next step is to consider whether there is a relevant exception, either for the purpose of achieving pregnancy in a woman, under a general licence, or under a mitochondrial donation licence.

For ART clinics creating embryos by IVF, compliance is relatively straightforward if the sole purpose is fertility treatment. Section 12(1)(a) exempts creation of an embryo by fertilisation outside the body if the intention is to attempt to achieve pregnancy in a particular woman. The clinic must ensure that the embryo is not developed outside the body for more than 14 days (section 14) and that it does not contain genetic material from more than two persons (unless under a mitochondrial donation licence). Written consent from the woman and her spouse (if any) is required before an embryo can be considered excess to needs (section 8(5)), which is necessary for any subsequent use of the embryo for research or donation.

Researchers wishing to conduct activities that are not for fertility treatment must obtain appropriate licences under the Research Involving Human Embryos Act 2002. This includes a general licence for activities such as creating embryos by other processes (e.g., somatic cell nuclear transfer), creating embryos with genetic material from more than two persons by non-fertilisation processes, using precursor cells to create embryos, or creating hybrid embryos. For mitochondrial donation techniques, a series of licences are available: pre-clinical research and training, clinical trial research and training, clinical trial, clinical practice research and training, and clinical practice licences (section 8 definition). Researchers must apply to the NHMRC Licensing Committee and comply with the conditions of any licence issued.

All persons handling human embryos must adhere to the 14-day development rule. Laboratories should maintain strict logbooks and automated timers that account for periods when development is suspended. If an embryo is cryopreserved, the development clock is paused. Each time the embryo is thawed and cultured, the clock starts again. The total active development time must not exceed 14 days.

Commercial entities must avoid any form of valuable consideration in exchange for gametes or embryos. The only permitted payments are for reasonable expenses related to collection, storage, or transport. For embryos, expenses incurred before the embryo became an excess ART embryo are not recoverable. Compliance requires clear documentation of all expenses and the written declaration of excess status from the relevant persons. Inducements, discounts, or priority services are prohibited.

Importers and exporters must ensure that no human embryo clones or prohibited embryos are brought into or sent out of Australia without appropriate approvals. The Customs Minister is required to make regulations permitting the import and export of human embryonic stem cell lines derived from human embryo clones using practices consistent with Australian legislation (section 23C). Until such regulations are made, such trade is prohibited. For other embryos, the definition of prohibited embryo in section 20(4) must be checked carefully before any cross-border movement.

Organisations should implement compliance policies, training, and auditing to ensure all staff understand the prohibitions and the importance of licence conditions. Legal advice should be sought where the activity involves novel techniques or where the status of an embryo is unclear. The Act provides protection for those acting under a purportedly valid licence that turns out to be invalid (section 23BA), but only if they did not know and could not reasonably be expected to have known of the invalidity. Regular checks on the validity of licences are essential.

Finally, entities subject to the Act must cooperate with any independent reviews undertaken under section 25. The Minister must cause a review every seven years in relation to mitochondrial donation techniques, and stakeholders should be prepared to provide input and documentation. Compliance with the Act is not optional; the penalties of up to 15 years' imprisonment underscore the seriousness of the prohibitions.